All In Biotech

Drug Trial Radar · NCT04400318

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma

Last checked: Nov 20, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 109 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

109

Actual

Start

Jun 20, 2020

Primary completion

Jun 26, 2023

Study completion Aug 21, 2023

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
May 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: • To assess the effect of dupilumab on lung inflammation and related changes in airway volumes detectable by functional respiratory imaging Secondary Objective: * To evaluate the effect of dupilumab at Week 24 on bronchodynamics, hyperinflation, airway resistance, airway wall thickness, ventilation defects and mucus plugging derived from high-resolution computed tomography (HRCT) scans, patient-reported outcomes, FeNO and spirometry. * To evaluate safety of dupilumab

Conditions

  • Asthma

Interventions

  • DupilumabDrug

    solution for injection subcutaneous

  • PlaceboDrug

    Solution for injection subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved Fractional Exhaled Nitric Oxide (FeNO) Less Than (<) 25 Parts Per Billion (Ppb) at Week 24Time frame: Week 24
  2. Percent Change From Baseline to Week 24 in Untrimmed Distal Specific Airway Volumes ([s]iVaw) at Total Lung Capacity (TLC)Time frame: Baseline (Day 1) to Week 24

Locations

65 sites in 13 countries. Site status is shown where the registry gives one.

  • Allianz Research Institute Site Number : 8400020

    Westminster, California

  • University of Kansas School of Medicine Site Number : 8400008

    Kansas City, Kansas

  • University of Michigan Site Number : 8400002

    Ann Arbor, Michigan

  • The Lung Research Center Site Number : 8400010

    Chesterfield, Missouri

  • American Health Research Site Number : 8400005

    Charlotte, North Carolina

  • Velocity Clinical Research, Medford Site Number : 8400014

    Medford, Oregon

  • Medical University of South Carolina - Pulmonary & Critical Care Clinical Research Program Site Number : 8400009

    Charleston, South Carolina

  • VitaLink Research-Greenville Site Number : 8400013

    Greenville, South Carolina

  • VitaLink Research - Spartanburg Site Number : 8400011

    Spartanburg, South Carolina

  • ~Spartanburg Medical Research Site Number : 8400004

    Spartanburg, South Carolina

  • Investigational Site Number : 1000013

    Dupnitsa, Bulgaria

  • Investigational Site Number : 1000004

    Montana, Bulgaria

  • Investigational Site Number : 1000018

    Plovdiv, Bulgaria

  • Investigational Site Number : 1000012

    Plovdiv, Bulgaria

  • Investigational Site Number : 1000008

    Rousse, Bulgaria

  • Investigational Site Number : 1000015

    Sofia, Bulgaria

  • Investigational Site Number : 1000005

    Sofia, Bulgaria

  • Investigational Site Number : 1000003

    Sofia, Bulgaria

  • Investigational Site Number : 1000006

    Sofia, Bulgaria

  • Investigational Site Number : 1000011

    Sofia, Bulgaria

  • Investigational Site Number : 1000010

    Sofia, Bulgaria

  • Investigational Site Number : 1000002

    Sofia, Bulgaria

  • Investigational Site Number : 1000007

    Stara Zagora, Bulgaria

  • Investigational Site Number : 2080006

    Aarhus N, Denmark

  • Investigational Site Number : 2080002

    Copenhagen, Denmark

  • Investigational Site Number : 2080003

    Copenhagen Nv, Denmark

  • Investigational Site Number : 2080001

    Hvidovre, Denmark

  • Investigational Site Number : 2500001

    Montpellier, France

  • Investigational Site Number : 3800001

    Pisa, Italy

  • Investigational Site Number : 3800003

    Cona, Ferrara, Italy

  • Investigational Site Number : 3800004

    Rozzano, Milano, Italy

  • Investigational Site Number : 6200004

    Coimbra, Portugal

  • Investigational Site Number : 6200005

    Guimarães, Portugal

  • Investigational Site Number : 6200006

    Lisbon, Portugal

  • Investigational Site Number : 6200003

    Porto, Portugal

  • Investigational Site Number : 6200001

    Porto, Portugal

  • Investigational Site Number : 6420005

    Bragadiru, Romania

  • Investigational Site Number : 6420008

    Brasov, Romania

  • Investigational Site Number : 6420006

    Cluj-Napoca, Romania

  • Investigational Site Number : 6420001

    Cluj-Napoca, Romania

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.